Jesse Wu - 31 Oct 2021 Form 4 Insider Report for LianBio (LIANY)

Reporting relationship: Director
Issuer ticker: LIANY
Reported as of: 31 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Nov 2021, 19:21:50 UTC
Prior SEC filing: 29 Oct 2021
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Jesse Wu filed Form 4 for LianBio (LIANY) on 01 Nov 2021.

Key facts

This page summarizes Jesse Wu's Form 4 filing for LianBio (LIANY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Nov 2021, 19:21.

Change

Previous filing in this sequence was filed on 29 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: -72,600
Change %: -50%
Price: $0.000000
Shares after: 72,600
Date: 31 Oct 2021
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 72,600
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36 of the shares underlying the option vested and became exercisable on October 31, 2021; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on October 31, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.